Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer

Several new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research